Shares of Hims & Hers Health Inc (NYSE:HIMS) climbed 2.4% in after-hours trading on Tuesday following disclosure of insider buying in a Securities and Exchange Commission filing.
The Form 4 shows that director David B. Wells purchased 48,400 shares of Class A Common Stock on May 26, 2026. The filing records an average weighted purchase price of $24.235 per share, with the individual trades executed at prices ranging from $24.19 to $24.25.
After the transaction was completed, Wells' direct holdings increased to 224,417 shares. The filing was submitted pursuant to Section 16(a) of the Securities Exchange Act of 1934, the federal rule that requires company insiders to disclose purchases and sales of their company’s securities.
Market participants commonly view insider purchases as a favorable signal because directors and executives generally have access to more detailed information about their companies' operations and strategic plans. In this case, the board member's acquisition of Class A stock has been characterized by market commentators as a vote of confidence in the telehealth company’s near-term prospects.
The after-hours price move followed the public disclosure of the transaction. While the immediate reaction was a modest uptick in the share price, the filing itself simply records the transaction details and the resulting change in the director's holdings rather than providing any new operational or financial data about the company.
This account is limited to the information set out in the SEC filing: the number of shares bought, the date of purchase, the price range and weighted average paid, the change in direct holdings, and the regulatory basis for the disclosure. The filing confirms compliance with the reporting obligation under Section 16(a) but does not include additional commentary from the company or the director about the rationale for the purchase.
Transaction details - key facts
- Buyer: Director David B. Wells
- Securities: 48,400 shares of Class A Common Stock
- Date: May 26, 2026
- Price: Average weighted price $24.235; individual trades between $24.19 and $24.25
- Holdings after trade: 224,417 shares directly held by Wells
- Regulatory filing: Form 4 filed under Section 16(a) of the Securities Exchange Act of 1934
The disclosure of an insider purchase and the subsequent after-hours movement in the stock are the only market events detailed in the filing. No additional company performance metrics, guidance changes, or operational updates accompany the Form 4, and there is no further commentary in the regulatory filing itself.